ELUTIA INC.

Develops drug-eluting biologics to reduce complications from medical implants.

ELUT | NDAQ

Overview

Corporate Details

ISIN(s):: US05479K1060
LEI:
Country:: United States of America
Address:: 12510 PROSPERITY DRIVE, 20904 SILVER SPRING
Website:: https://elutia.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Elutia Inc. is a commercial-stage company that develops and commercializes drug-eluting biologic products to improve compatibility between medical devices and patients. The company's proprietary drug-eluting biomaterial platforms combine natural biologic materials with extended-release antibiotics to address post-surgical complications from implant failures. Its key offerings include CanGaroo, an acellular device envelope for implantable electronics like pacemakers and neurostimulators, and SimpliDerm, a human acellular dermal matrix for soft tissue reconstruction. These products are designed to mitigate fibrotic responses, ensure implant stability, and support wound healing. Formerly known as Aziyo Biologics, the company rebranded to Elutia to reflect its strategic focus on drug-eluting biomatrices.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all ELUTIA INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ELUTIA INC.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for ELUTIA INC. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Entrada Therapeutics, Inc. Developing intracellular therapeutics for rare neuromuscular diseases via its EEV™ platform.	United States of America	TRDA
ENZYCHEM LIFESCIENCES CORPORATION Develops novel therapeutics and APIs for oncology, inflammation, and respiratory diseases.	South Korea	183490
Enzymatica AB Develops medical devices with patented enzyme technology to treat upper respiratory infections.	Sweden	ENZY
Epi Biotech Co., Ltd. Developing alopecia therapies, skin regeneration products, and preclinical CRO services.	South Korea	446440
EQL Pharma AB Develops and sells cost-efficient niche generic medicines for the Nordic healthcare market.	Sweden	EQL
Equillium, Inc. Clinical-stage biotech creating therapies for severe autoimmune and inflammatory disorders.	United States of America	EQ
Erasca, Inc. Clinical-stage oncology company developing therapies targeting the RAS/MAPK pathway in cancer.	United States of America	ERAS
Ernexa Therapeutics Inc. Developing targeted, off-the-shelf cell therapies for cancer and autoimmune diseases.	United States of America	ERNA
ERYTECH Pharma S.A. Developing phage therapies to combat antibiotic-resistant bacterial infections.	France	ERYP
Esperion Therapeutics, Inc. Develops oral ACLY inhibitors to lower high LDL-C and cardiovascular risk.	United States of America	ESPR